



- History of the disease:



- In 1901, William Leishman identified certain organisms in smears taken from the spleen of a patient who had died from dum-dum fever in India.
- In 1903, Charles Donovan described them as being new organisms.

- Leishmania:

- **Type:** protozoan parasite.

- **It is present in two forms:**

- ✓ Motile promastigotes (which are present in the vector: sand-fly).
- ✓ Non-motile amastigotes (which are present in macrophages of mammalian hosts).



- **Disease which they cause is called: Leishmaniasis. This disease is present in 3 forms:**

- ✓ Cutaneous: infection remains localized (ulcer).

It is caused by:


- ❖ *L.major.*
- ❖ *L.tropica.*
- ❖ *L.aethiopica.*

- ✓ Mucocutaneous: results from immune reaction. It is caused by:

- ❖ *L.braziliensis* (south and central America).

- ✓ Visceral: no local ulcer (parasites disseminate to liver, spleen & bone marrow). It is caused by:

- ❖ *L.donovani*
- ❖ *L.chagasi* (south America).
- ❖ *L.infantum*



- **Epidemiology:**

- ✓ There are 12 million cases worldwide (1.5-2 million cases annually).


- ✓ Classified into:

- ❖ *Old world* (Asia, Africa and Mediterranean).
- ❖ *New world* (Americas).

- ✓ Transmitted by: different species of sandflies:

- ❖ *Old world:* Phlebotomus.
- ❖ *New world:* Lutzomyia.

- ✓ Reservoir hosts: rodents and domestic dogs.




- **Life cycle:**

- ✓ Infective stage: a female sandfly takes a blood meal from a human injecting metacyclic promastigotes in his skin.

- ✓ Diagnostic stage: promastigotes will be phagocytized by macrophages in which the promastigotes will transform to amastigotes and multiply there (intracellularly) escaping the host defense by being resistant to lysosomal enzymes.



- ✓ A female sandfly will take a blood meal (ingesting macrophages infected with amastigotes).
- ✓ Parasitized cells will be ingested and amastigotes will transform to promastigote stage in the midgut of the female sandfly.



- **Diagnosis & outcome of the disease:**

- ✓ Cutaneous:

- ❖ It is self-limited.
- ❖ Ulcers heal in few months leaving scars.
- ❖ In some individuals it may become chronic.
- ❖ *Diagnosis of cutaneous leishmaniasis:*
  - ✚ Clinical manifestations + demonstration of parasites from the ulcer (smear or culture).
  - ✚ Montenegro test: delayed hypersensitivity skin test with killed promastigotes.

- ✓ Mucocutaneous:

- ❖ In 1-3% of patients, there will be metastatic spread to nasal, pharyngeal and buccal mucosa.
- ❖ May appear months to years after initial lesion has healed.

- ✓ Visceral:

- ❖ Organisms disseminate to liver, spleen and bone marrow.
- ❖ *Incubation period:* 2-6 months.
- ❖ *Clinical features:* chronic fever, hepatomegaly, splenomegaly, anemia, leucopenia and hypergammaglobulinemia.
- ❖ *Prognosis:* high fatality rate if untreated.
- ❖ Post Kala-Azar Dermal Leishmaniasis (PKDL).
- ❖ *Diagnosis of visceral leishmania:*
  - ✚ Demonstration of parasites by tissue aspirates:
    - Liver.
    - Spleen (sensitivity > 98%) but there is a hemorrhage risk to the patient.
    - Sterna bone marrow (sensitivity 60-85%).
  - ✚ Parasite culture: not useful diagnostically.



- ✚ Inoculation of laboratory animals (hamsters, mice, guinea pigs): not usually performed for routine diagnosis.
- ✚ Immunodiagnosis:
  - Antigens detected in urine (Kala-Azar).
  - Antibody detection: IFA, DAT, ELISA and skin testing.
- ✚ DNA detection: PCR
- **Prevention and control:**
  - ✓ Pentavalent antimony drugs (details in pharmacology note).
  - ✓ Avoidance of sandfly bites by:
    - ❖ Use of insecticides.
    - ❖ Sleeping under bed net.
  - ✓ Vaccination: which is produced in Razi institute in Tehran-Iran.